UNLOCKING THE POTENTIAL OF PLASMID-BASED ANTIBODY GENE TRANSFER KU Leuven
Recombinant monoclonal antibodies (mAbs) continue to gain impact in the clinic. However, their broader implementation is restricted by a number of limitations. This includes a costly production process, the long-term need for frequent high dosing, which is associated with adverse events and increased financial burden for health-care systems and patients, and a limited single-agent therapeutic efficacy.The Antibody Gene Transfer (AGT) Program in ...